Salivary epithelial-myoepithelial carcinoma : clinical, morphological and molecular features
© Copyright Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology..
Epithelial-myoepithelial carcinoma (EMC) is a rare biphasic tumor accounting for less than 2% of all salivary gland malignancies. It presents as a slowly growing, asymptomatic small size mass, with ulceration of overlying mucosa in some cases. Microscopically, it is characterized by glands lined by the simultaneous presence of two different cell components, inner epithelial cells and outer myoepithelial cells. Immunohistochemical staining of myoepithelial cells is variably positive for vimentin, Smooth Muscle Actin (SMA), Muscle Specific Actin (MSA), S100, Smooth Muscle Myosin Heavy Chain I(SM-MHC), calponin and p63. Several molecular alterations, mainly point mutations, have been described. Mutations of HRAS, AKT1, CTNNB1 and PIK3CA were highlighted in variable percentage of EMC samples. EMC is considered a low-grade malignant tumor with a 5-year survival rate of 94% that may commonly recur locally after resection in 30-50% of cases. At the moment, adequate resection with negative margins is the minimum recommended and necessary treatment.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:109 |
|---|---|
| Enthalten in: |
Pathologica - 109(2017), 1 vom: 01. März, Seite 1-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
De Cecio, R [VerfasserIn] |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 16.07.2018 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM273141236 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM273141236 | ||
| 003 | DE-627 | ||
| 005 | 20231225000502.0 | ||
| 007 | tu | ||
| 008 | 231225s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0910.xml |
| 035 | |a (DE-627)NLM273141236 | ||
| 035 | |a (NLM)28635988 | ||
| 035 | |a (PII)Pacini | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a De Cecio, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Salivary epithelial-myoepithelial carcinoma |b clinical, morphological and molecular features |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 16.07.2018 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Copyright Società Italiana di Anatomia Patologica e Citopatologia Diagnostica, Divisione Italiana della International Academy of Pathology. | ||
| 520 | |a Epithelial-myoepithelial carcinoma (EMC) is a rare biphasic tumor accounting for less than 2% of all salivary gland malignancies. It presents as a slowly growing, asymptomatic small size mass, with ulceration of overlying mucosa in some cases. Microscopically, it is characterized by glands lined by the simultaneous presence of two different cell components, inner epithelial cells and outer myoepithelial cells. Immunohistochemical staining of myoepithelial cells is variably positive for vimentin, Smooth Muscle Actin (SMA), Muscle Specific Actin (MSA), S100, Smooth Muscle Myosin Heavy Chain I(SM-MHC), calponin and p63. Several molecular alterations, mainly point mutations, have been described. Mutations of HRAS, AKT1, CTNNB1 and PIK3CA were highlighted in variable percentage of EMC samples. EMC is considered a low-grade malignant tumor with a 5-year survival rate of 94% that may commonly recur locally after resection in 30-50% of cases. At the moment, adequate resection with negative margins is the minimum recommended and necessary treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Pathologic and molecular features | |
| 650 | 4 | |a Prognosis and treatment | |
| 650 | 4 | |a Salivary epithelial-myoepithelial carcinoma | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Cantile, M |e verfasserin |4 aut | |
| 700 | 1 | |a Fulciniti, F |e verfasserin |4 aut | |
| 700 | 1 | |a Botti, G |e verfasserin |4 aut | |
| 700 | 1 | |a Foschini, M P |e verfasserin |4 aut | |
| 700 | 1 | |a Losito, N S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pathologica |d 1945 |g 109(2017), 1 vom: 01. März, Seite 1-8 |w (DE-627)NLM000278947 |x 1591-951X |7 nnns |
| 773 | 1 | 8 | |g volume:109 |g year:2017 |g number:1 |g day:01 |g month:03 |g pages:1-8 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 109 |j 2017 |e 1 |b 01 |c 03 |h 1-8 | ||